Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Natalia Geyvandova"'
Autor:
Heiner Wedemeyer, Soo Aleman, Maurizia Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Dmitry Manuilov, Vithika Suri, Qi An, John Flaherty, Anu Osinusi, JulianSchulze zur Wiesch, Markus Cornberg, Stefan Zeuzem, Pietro Lampertico
Publikováno v:
39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ffeffdab2557c488c9eabe8dc7cb359
https://doi.org/10.1055/s-0042-1760042
https://doi.org/10.1055/s-0042-1760042
Autor:
Stacey Lee, Heiner Wedemeyer, Soo Aleman, Maurizia Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Dmitry Manuilov, Vithika Suri, Qi An, John F. Flaherty, Anu Osinusi, Julian Schulze zur Wiesch, Markus Cornberg, Stefan Zeuzem, Pietro Lampertico
Publikováno v:
American Journal of Gastroenterology. 117:e858-e859
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fd563043884da7f6d6b6fbeecd689e9
https://doi.org/10.14309/01.ajg.0000861356.43387.47
https://doi.org/10.14309/01.ajg.0000861356.43387.47
Autor:
Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, Antje Blank, Natalia Voronkova, Tatiana Stepanova, Olga Sagalova, Vladimir Chulanov, Marina Osipenko, Viacheslav Morozov, Natalia Geyvandova, Snezhana Sleptsova, Igor G Bakulin, Ilsiyar Khaertynova, Marina Rusanova, Anita Pathil, Uta Merle, Birgit Bremer, Lena Allweiss, Florian A Lempp, Kerstin Port, Mathias Haag, Matthias Schwab, Julian Schulze zur Wiesch, Markus Cornberg, Walter E Haefeli, Maura Dandri, Alexander Alexandrov, Stephan Urban
Publikováno v:
The Lancet. Infectious diseases. 23(1)
Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV) and hepatitis D virus infection. In July, 2020, bulevirtide 2 mg received conditional marketing authorisation by the European Medical Agency for treatment of chronic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41ee82bb0f47542eb9868be2979051d5
https://pubmed.ncbi.nlm.nih.gov/36354036
https://pubmed.ncbi.nlm.nih.gov/36354036
Autor:
Michael J. McKenna, Maribel Rodriguez–Torres, K. Rajender Reddy, Michael Rabbia, Stephen A. Harrison, James Thommes, Hugo Cheinquer, Natalia Geyvandova, Igor G. Bakulin, Giovanni Faria Silva, Carol Stanciu, Viacheslav Morozov, Mitchell L. Shiffman, Djamal Abdurakhmanov
Publikováno v:
Gastroenterology. 139(6)
Patients infected with hepatitis C virus (HCV) genotype 1, body weight ≥85 kg, and high baseline viral load respond poorly to standard doses of pegylated interferon (peginterferon) and ribavirin. We evaluated intensified therapy with peginterferon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08014193c1165ca204b6d736e31b49b2
https://pubmed.ncbi.nlm.nih.gov/20816836
https://pubmed.ncbi.nlm.nih.gov/20816836